Domitroban

{{Drugbox | Verifiedfields = changed | verifiedrevid = 477241123 | IUPAC_name = 2-[2-[(3R)-3-[[4-(4-chlorophenyl)butanoyl]amino]-3-(4-hydroxyphenyl)propyl]phenoxy]acetic acid | image = Domitroban.svg | width = 250 | CAS_number = 105826-92-4 | ATC_prefix = none | PubChem = 65656 | ChemSpiderID = 59090 | UNII = 0F5N573A2Y | KEGG = D07865 | ChEMBL = 2104660 | C=27 | H=28 | Cl=1 | N=1 | O=5 | smiles = C1=CC=C(C=C1)C[C@@H](C(=O)NCCCC2=CC=C(C=C2)Cl)C3=CC=C(C=C3)OCC(=O)O | StdInChI = 1S/C27H28ClNO5/c28-22-10-8-20(9-11-22)14-5-6-15-29-26(32)23-12-7-19(18-24(23)29)13-17-3-1-2-4-21(17)25(30)27(31)33-16-13/h1-4,7-12,18,25,30H,5-6,14-16H2,(H,31,33)/t25-/m1/s1 | StdInChIKey = ZQXJXKQXQZQXQZ-UHFFFAOYSA-N }}

Domitroban is a pharmaceutical compound that acts as a selective thromboxane receptor antagonist. It is primarily studied for its potential therapeutic effects in conditions related to platelet aggregation and vascular constriction, such as thrombosis and atherosclerosis.

Pharmacology

Domitroban works by inhibiting the action of thromboxane A2, a potent vasoconstrictor and promoter of platelet aggregation. Thromboxane A2 is a product of the arachidonic acid pathway and plays a significant role in the pathophysiology of cardiovascular diseases. By blocking the thromboxane receptor, Domitroban reduces platelet aggregation and vasoconstriction, potentially lowering the risk of thrombotic events.

Mechanism of Action

The mechanism of action of Domitroban involves competitive inhibition at the thromboxane receptor site. This prevents thromboxane A2 from binding to its receptor, thereby inhibiting its effects on platelets and vascular smooth muscle cells. The result is a decrease in platelet aggregation and vasodilation, which can be beneficial in preventing conditions like myocardial infarction and stroke.

Clinical Applications

While Domitroban has shown promise in preclinical studies, its clinical applications are still under investigation. It is being studied for its potential use in treating cardiovascular diseases, particularly those involving excessive platelet aggregation and vasoconstriction. However, more research is needed to fully understand its efficacy and safety profile in humans.

Research and Development

Research on Domitroban has primarily focused on its role as a thromboxane receptor antagonist. Studies have explored its effects in animal models of thrombosis and atherosclerosis, with some promising results. However, clinical trials are necessary to determine its potential as a therapeutic agent in humans.

Safety and Side Effects

As with any pharmacological agent, the safety and side effect profile of Domitroban is an important consideration. Potential side effects may include bleeding complications due to its antiplatelet effects. Further studies are required to establish a comprehensive safety profile.

Also see

• Thromboxane
• Platelet aggregation
• Vasoconstriction
• Arachidonic acid
• Cardiovascular disease